Brivanib Studied in First- and Second-Line Therapy for Advanced Hepatocellular Carcinoma The ASCO Post, 13 Nov 2013 The investigational drug brivanib is a dual inhibitor of vascular endothelial growth factor and fibroblast growth factor…